KDTV001 cervical lesion study stays recruiting in phase 1 and phase 2 — LiveFuture News
Open on LiveFuture.ai →

KDTV001 cervical lesion study stays recruiting in phase 1 and phase 2

A ClinicalTrials.gov registry observation shows KDTV001 is recruiting in phase 1 and phase 2 for cervical high-grade squamous intraepithelial lesion linked to HPV types 16, 18, and 52, with outcomes still pending.

Watch this video →

A new ClinicalTrials.gov registry observation shows KDTV001 Injection in Patients With Human Papillomavirus (HPV) Types 16, and/or 18, and/or 52 Associated Cervical High-Grade Squamous Intraepithelial Lesion . is recruiting. The study is in PHASE1, PHASE2, and the current status is RECRUITING, so the practical takeaway is simple: the project is open, but posted results are not yet available.

That status was published 2026-11-19T00:00:00+00:00. The sponsor is Wuhan KadGeno Biotechnology Co., Ltd, and the study has no results posted yet, which means the registry entry describes plans and endpoints rather than a finished outcome.

How the study is set up

The trial is NON_RANDOMIZED and includes four experimental arm groups: Cohort A Dose Level 1, Cohort A Dose Level 2, Cohort B Dose Level 1, and Cohort B Dose Level 2. The intervention listed is KDTV001, a drug, with each arm tied to those cohort labels.

For phase 1, the main measure is safety: the incidence of Any Adverse Events (AEs), Treatment related AEs (TRAEs) and Serious Adverse Events (SAEs) from enrollment to 2 years after the first dose. For phase 2, the goal is broader and more clinical: the percentage of participants with no evidence of cervical HSIL on histology and no evidence of HPV-16 and HPV-18 and HPV-52 in cervical samples.

What the phase 2 measure means in plain language

Cervical HSIL means high-grade squamous intraepithelial lesion, a serious precancerous change in the cervix. In this study, a response is defined around histology results and HPV testing at the Week 36 time frame, with the record stating that excision or biopsy sample not obtained between the initial dose up to Week 36 were considered to be responders.

The record also says HPV testing will be performed using the cobas® assay and a second assay kit manufactured in China to identify HPV 52. The primary completion date is listed as 2027-11-30 and marked ESTIMATED, so this remains an in-progress study with a future readout date rather than a settled result.

Why it fits the wider cancer research picture

This registry observation sits within the active special event Cancer Breakthroughs, alongside other recruiting or not-yet-recruiting studies that are also trying to answer practical treatment questions. For readers tracking the field, the common thread is that many cancer studies are still in the stage of opening enrollment and defining outcome measures rather than reporting final answers.

Related entries in the same event include the Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer and A Study to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight (VESPER-SUI). They are different conditions, but they show the same pattern of active trial registration and pending evidence.